12:20 PM
 | 
Oct 10, 2018
 |  BC Extra  |  Company News

BARDA, J&J partner against chemical, biological and nuclear threats

HHS’s Biomedical Advanced Research and Development Authority partnered with Johnson & Johnson (NYSE:JNJ) to develop products to fight chemical, biological, radiation and nuclear threats, infectious diseases and antimicrobial resistant infections.

BARDA will initially provide more than $28 million over two...

Read the full 176 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >